Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALT Altimmune	$3.83 +3.2%	$4.12	$2.90 ▼ $11.16	$338.02M	-0.01	2.97 million shs	2.74 million shs
INSP Inspire Medical Systems	$93.86 +2.6%	$113.86	$73.92 ▼ $225.00	$2.77B	1.22	1.73 million shs	656,389 shs
LLY Eli Lilly and Company	$732.41 +0.1%	$748.68	$623.78 ▼ $969.65	$693.36B	0.44	6.90 million shs	2.55 million shs
NVO Novo Nordisk A/S	$56.51 +0.7%	$60.72	$45.05 ▼ $139.74	$252.09B	0.63	20.46 million shs	9.10 million shs
RMD ResMed	$274.78 -0.2%	$270.83	$199.92 ▼ $293.81	$40.19B	0.77	1.04 million shs	1.33 million shs
VKTX Viking Therapeutics	$27.05 -1.9%	$31.19	$18.92 ▼ $81.73	$3.04B	0.67	9.75 million shs	3.79 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALT Altimmune	0.00%	+8.19%	+3.79%	-29.47%	-40.90%
INSP Inspire Medical Systems	0.00%	-2.02%	-24.63%	-32.00%	-48.77%
LLY Eli Lilly and Company	0.00%	+3.05%	-0.97%	-0.80%	-22.82%
NVO Novo Nordisk A/S	0.00%	-0.68%	+20.17%	-20.86%	-57.98%
RMD ResMed	0.00%	-6.37%	+0.96%	+12.33%	+13.22%
VKTX Viking Therapeutics	0.00%	+4.04%	-16.95%	+0.26%	-55.77%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALT Altimmune	3.2494 of 5 stars	4.3	3.0	0.0	0.0	2.4	1.7	0.6
INSP Inspire Medical Systems	4.9827 of 5 stars	4.3	4.0	0.0	4.8	4.1	1.7	3.1
LLY Eli Lilly and Company	5 of 5 stars	4.3	5.0	3.3	4.0	3.1	3.3	3.8
NVO Novo Nordisk A/S	4.5702 of 5 stars	4.1	5.0	2.5	0.0	2.6	0.0	3.1
RMD ResMed	4.6857 of 5 stars	2.4	2.0	3.3	4.6	3.5	1.7	2.5
VKTX Viking Therapeutics	3.7737 of 5 stars	3.5	1.0	0.0	4.7	2.2	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALT Altimmune	2.57	Moderate Buy	$17.40	354.31% Upside
INSP Inspire Medical Systems	2.54	Moderate Buy	$165.62	76.44% Upside
LLY Eli Lilly and Company	2.67	Moderate Buy	$950.17	29.73% Upside
NVO Novo Nordisk A/S	2.13	Hold	$81.00	43.35% Upside
RMD ResMed	2.81	Moderate Buy	$274.83	0.02% Upside
VKTX Viking Therapeutics	3.00	Buy	$86.92	221.34% Upside

Current Analyst Ratings Breakdown

Latest LLY, NVO, VKTX, ALT, RMD, and INSP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2025	LLY Eli Lilly and Company	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Reduce ➝ Hold	$675.00 ➝ $700.00
8/27/2025	LLY Eli Lilly and Company	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Sell ➝ Hold
8/22/2025	NVO Novo Nordisk A/S	Dbs Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/20/2025	NVO Novo Nordisk A/S	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/19/2025	NVO Novo Nordisk A/S	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$105.00 ➝ $70.00
8/19/2025	VKTX Viking Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$102.00
8/17/2025	LLY Eli Lilly and Company	Daiwa Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$700.00
8/17/2025	LLY Eli Lilly and Company	Daiwa America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/15/2025	INSP Inspire Medical Systems	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Perform ➝ Market Perform	$116.00 ➝ $97.00
8/14/2025	LLY Eli Lilly and Company	DZ Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/13/2025	LLY Eli Lilly and Company	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$975.00 ➝ $825.00

(Data available from 8/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALT Altimmune	$20K	16,901.79	N/A	N/A	$1.83 per share	2.09
INSP Inspire Medical Systems	$802.80M	3.46	$1.71 per share	54.83	$22.92 per share	4.10
LLY Eli Lilly and Company	$45.04B	15.39	$14.23 per share	51.46	$19.39 per share	37.77
NVO Novo Nordisk A/S	$42.12B	5.99	$3.90 per share	14.47	$5.73 per share	9.86
RMD ResMed	$5.15B	7.82	$11.21 per share	24.51	$40.76 per share	6.74
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	$7.07 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALT Altimmune	-$95.06M	-$1.18	N/A	N/A	N/A	-438,730.03%	-62.63%	-55.29%	11/11/2025 (Estimated)
INSP Inspire Medical Systems	$53.51M	$1.73	54.26	29.15	2.92	6.17%	10.38%	8.93%	11/3/2025 (Estimated)
LLY Eli Lilly and Company	$10.59B	$15.30	47.87	23.54	1.02	25.91%	92.72%	16.89%	10/29/2025 (Estimated)
NVO Novo Nordisk A/S	$14.64B	$3.64	15.52	12.13	1.96	35.60%	78.64%	24.51%	11/5/2025 (Estimated)
RMD ResMed	$1.40B	$9.51	28.89	26.52	1.83	27.22%	25.62%	18.69%	10/23/2025 (Estimated)
VKTX Viking Therapeutics	-$109.96M	-$1.53	N/A	N/A	N/A	N/A	-19.98%	-19.38%	10/22/2025 (Estimated)

Latest LLY, NVO, VKTX, ALT, RMD, and INSP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	ALT Altimmune	-$0.32	-$0.27	+$0.05	-$0.27	$0.00 million	$0.01 million
8/7/2025	Q2 2025	LLY Eli Lilly and Company	$5.59	$6.31	+$0.72	$6.29	$14.40 billion	$15.56 billion
8/6/2025	Q2 2025	NVO Novo Nordisk A/S	$0.93	$0.97	+$0.04	$0.91	$77.51 billion	$11.69 billion
8/4/2025	Q2 2025	INSP Inspire Medical Systems	$0.22	$0.45	+$0.23	-$0.12	$214.50 million	$217.09 million
7/31/2025	Q4 2025	RMD ResMed	$2.47	$2.55	+$0.08	$2.58	$1.33 billion	$1.35 billion
7/23/2025	Q2 2025	VKTX Viking Therapeutics	-$0.44	-$0.58	-$0.14	-$0.58	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALT Altimmune	N/A	N/A	N/A	N/A	N/A
INSP Inspire Medical Systems	N/A	N/A	N/A	N/A	N/A
LLY Eli Lilly and Company	$6.00	0.82%	N/A	39.22%	11 Years
NVO Novo Nordisk A/S	$0.82	1.45%	N/A	22.53%	N/A
RMD ResMed	$2.40	0.87%	N/A	25.24%	13 Years
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	N/A

Latest LLY, NVO, VKTX, ALT, RMD, and INSP Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/31/2025	RMD ResMed	quarterly	$0.60	0.88%	8/14/2025	8/14/2025	9/18/2025
6/23/2025	LLY Eli Lilly and Company	quarterly	$1.50	0.78%	8/15/2025	8/15/2025	9/10/2025
8/6/2025	NVO Novo Nordisk A/S	semi-annual	$0.4119	2.4%	8/18/2025	8/18/2025	8/26/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALT Altimmune	0.09	20.44	20.44
INSP Inspire Medical Systems	N/A	6.14	4.84
LLY Eli Lilly and Company	1.86	1.28	1.00
NVO Novo Nordisk A/S	0.52	0.78	0.56
RMD ResMed	0.11	3.44	2.53
VKTX Viking Therapeutics	N/A	25.86	25.86

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALT Altimmune	78.05%
INSP Inspire Medical Systems	94.91%
LLY Eli Lilly and Company	82.53%
NVO Novo Nordisk A/S	11.54%
RMD ResMed	54.98%
VKTX Viking Therapeutics	76.03%

Insider Ownership

Company	Insider Ownership
ALT Altimmune	4.40%
INSP Inspire Medical Systems	4.10%
LLY Eli Lilly and Company	0.13%
NVO Novo Nordisk A/S	0.07%
RMD ResMed	0.71%
VKTX Viking Therapeutics	4.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALT Altimmune	50	88.26 million	84.37 million	Optionable
INSP Inspire Medical Systems	1,246	29.57 million	28.36 million	Optionable
LLY Eli Lilly and Company	47,000	946.46 million	945.23 million	Optionable
NVO Novo Nordisk A/S	77,349	4.47 billion	4.46 billion	Optionable
RMD ResMed	10,600	146.41 million	145.38 million	Optionable
VKTX Viking Therapeutics	20	112.44 million	107.84 million	Optionable

LLY, NVO, VKTX, ALT, RMD, and INSP Headlines

Recent News About These Companies

Raymond James Financial Inc. Buys 28,922 Shares of Viking Therapeutics, Inc. $VKTX

1 hour ago | marketbeat.com

Viking Therapeutics, Inc. (VKTX) Suffers a Larger Drop Than the General Market: Key Insights

August 29 at 6:46 PM | zacks.com

Viking Therapeutics to Participate at Upcoming Investor Conferences

August 28 at 4:30 PM | prnewswire.com

Affinity Asset Advisors LLC Acquires Shares of 25,000 Viking Therapeutics, Inc. $VKTX

August 28 at 9:09 AM | marketbeat.com

Viking Therapeutics, Inc. $VKTX Shares Sold by Russell Investments Group Ltd.

August 28 at 3:37 AM | marketbeat.com

Novo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock is a Safer Bet?

August 27, 2025 | zacks.com

Nuveen LLC Buys Shares of 384,379 Viking Therapeutics, Inc. $VKTX

August 26, 2025 | marketbeat.com

Short Report: Viking Therapeutics short interest at 5-year high after VK273 data

August 25, 2025 | msn.com

Viking Therapeutics, Inc. $VKTX Shares Sold by Charles Schwab Investment Management Inc.

August 25, 2025 | marketbeat.com

2 Biotech Stocks That Could Soar 21% and 245% According to Wall Street's Top Analysts

August 24, 2025 | fool.com

Is Viking Therapeutics stock a bargain after this week’s sell-off?

August 23, 2025 | msn.com

Analysts Set Viking Therapeutics, Inc. (NASDAQ:VKTX) Price Target at $86.92

August 23, 2025 | americanbankingnews.com

Viking Therapeutics (VKTX) Down 23.4% Since Last Earnings Report: Can It Rebound?

August 22, 2025 | msn.com

Viking Therapeutics (VKTX) Reports Increased Net Losses For Second Quarter

August 22, 2025 | finance.yahoo.com

Here's Why Shares in Viking Therapeutics Crashed This Week

August 22, 2025 | msn.com

Viking Therapeutics (VKTX) Rebounds on Bargain-Hunting. Are You Missing Out?

August 21, 2025 | insidermonkey.com

A Closer Look at Viking Therapeutics's Options Market Dynamics

August 21, 2025 | benzinga.com

Post Obesity Pill Results Reveal: Buy, Sell or Hold VKTX Stock?

August 21, 2025 | zacks.com

Viking Therapeutics (NASDAQ:VKTX) Shares Gap Down - Time to Sell?

August 21, 2025 | marketbeat.com

HC Wainwright Reiterates Buy Rating for Viking Therapeutics (NASDAQ:VKTX)

August 21, 2025 | marketbeat.com

Viking Therapeutics Sees Unusually High Options Volume (NASDAQ:VKTX)

August 21, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

LLY, NVO, VKTX, ALT, RMD, and INSP Company Descriptions

Altimmune NASDAQ:ALT

$3.83 +0.12 (+3.23%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$3.79 -0.04 (-1.15%)

As of 08/29/2025 07:58 PM Eastern

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Inspire Medical Systems NYSE:INSP

$93.86 +2.40 (+2.63%)

Closing price 08/29/2025 03:59 PM Eastern

Extended Trading

$92.75 -1.11 (-1.19%)

As of 08/29/2025 05:11 PM Eastern

Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.

Eli Lilly and Company NYSE:LLY

$732.41 +0.45 (+0.06%)

Closing price 08/29/2025 03:59 PM Eastern

Extended Trading

$731.25 -1.16 (-0.16%)

As of 08/29/2025 08:00 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S NYSE:NVO

$56.50 +0.40 (+0.70%)

Closing price 08/29/2025 03:59 PM Eastern

Extended Trading

$56.45 -0.05 (-0.10%)

As of 08/29/2025 08:00 PM Eastern

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

ResMed NYSE:RMD

$274.77 -0.61 (-0.22%)

Closing price 08/29/2025 03:59 PM Eastern

Extended Trading

$271.50 -3.27 (-1.19%)

As of 08/29/2025 04:56 PM Eastern

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Viking Therapeutics NASDAQ:VKTX

$27.05 -0.53 (-1.92%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$27.14 +0.09 (+0.31%)

As of 08/29/2025 07:59 PM Eastern

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LLY, NVO, VKTX, ALT, RMD, and INSP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LLY, NVO, VKTX, ALT, RMD, and INSP Earnings

Compare Dividends

Latest LLY, NVO, VKTX, ALT, RMD, and INSP Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LLY, NVO, VKTX, ALT, RMD, and INSP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

LLY, NVO, VKTX, ALT, RMD, and INSP Company Descriptions

Altimmune NASDAQ:ALT

Inspire Medical Systems NYSE:INSP

Eli Lilly and Company NYSE:LLY

Novo Nordisk A/S NYSE:NVO

ResMed NYSE:RMD

Viking Therapeutics NASDAQ:VKTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools